# Precede Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/precede-biosciences

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.precede.bio
- Total disclosed funding: $121M
- Latest round: Series B (Jan 12, 2026)
- Investors on record: 13

## About

Founded in 2021 and based in Massachusetts, US, Precede Biosciences, Inc. is a designer of advanced precision medicine with liquid biopsy technology. The company was co-founded by its CEO, Rehan Verjee. In January 2026, Precede Biosciences, Inc. raised USD 63.5 million in series B funding from investors LabCorp Ventures, UPMC Enterprises, Mirae Asset Capital Life Science, Mirae Asset Capital, 28 Ventures, Alexandria Venture Investments, Illumina Ventures, 5AM Ventures, Bristol-Myers Squibb Company, OUP (Osage University Partners), Binney Street Capital and Lilly Asia Ventures.The round was part of a larger USD 83.5 million series B and debt funding.

The company develops a liquid biopsy platform that reveals actionable disease-defining transcriptional biology through a minimally invasive blood test. The firm’s platform profiles circulating chromatin and DNA methylomes from just 1 mL of plasma. This genome-wide analysis provides insights into the activation of individual genes and pathways. Precede Biosciences' approach analyzes DNA methylomes from plasma and circulating chromatin, giving researchers and physicians an understanding of how specific genes and pathways are dynamically activated in sick tissues.

The company plans to use the January 2026 funding to scale its platform to meet growing demand from developers of next-generation precision medicines.

## Funding rounds

- Series B, Jan 12, 2026, $64M — Alexandria Venture Investments, 5AM Ventures, OUP (Osage University Partners), Lilly Asia Ventures, Bristol-Myers Squibb Company, Illumina Ventures, LabCorp Ventures, Binney Street Capital, Mirae Asset Capital, Mirae Asset Capital Life Science, 28 Ventures, UPMC Enterprises
- Series A, Oct 5, 2023, $57M — 5AM Ventures, OUP (Osage University Partners), Qatar Investment Authority, Lilly Asia Ventures, Bristol-Myers Squibb Company, Illumina Ventures
- Seed, Jun 1, 2022 — 5AM Ventures, Binney Street Capital

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed, Series A, Series B
- Binney Street Capital (https://capitalatlas.ai/funds/binney-street-capital) — Seed, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- Qatar Investment Authority (https://capitalatlas.ai/funds/qatar-investment-authority) — Series A
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Bristol-Myers Squibb Company — Series A, Series B
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series A, Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- LabCorp Ventures (https://capitalatlas.ai/funds/labcorp-ventures) — Series B
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series B
- Mirae Asset Capital Life Science (https://capitalatlas.ai/funds/mirae-asset-capital-life-science) — Series B
- 28 Ventures (https://capitalatlas.ai/funds/28-ventures) — Series B
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series B